bevacizumab biosimilar (Sunshine Lake Pharma/HEC Pharm)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Namebevacizumab biosimilar (Sunshine Lake Pharma/HEC Pharm)
Drug Alias Namebevacizumab biosimilar (Guangdong HEC Pharmaceutical)recombinant anti-VEGF humanized monoclonal antibody (HEC Pharm)
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVascular endothelial growth factor inhibitors
TargetsVascular endothelial growth factor
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesGuangdong Hec Technology Holding Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGuangdong Hec Technology Holding Co LtdDongguan City Hec Biological Medicine Res And Development Co Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A